Lantheus (LNTH) Competitors $79.78 +0.97 (+1.23%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LNTH vs. ONC, BNTX, SMMT, TEVA, ITCI, GMAB, RDY, MRNA, ASND, and VTRSShould you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Beigene (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Ascendis Pharma A/S (ASND), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Lantheus vs. Beigene BioNTech Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Ascendis Pharma A/S Viatris Lantheus (NASDAQ:LNTH) and Beigene (NASDAQ:ONC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations. Is LNTH or ONC more profitable? Lantheus has a net margin of 28.57% compared to Beigene's net margin of -25.94%. Lantheus' return on equity of 44.29% beat Beigene's return on equity.Company Net Margins Return on Equity Return on Assets Lantheus28.57% 44.29% 23.52% Beigene -25.94%-25.12%-14.95% Which has higher earnings and valuation, LNTH or ONC? Lantheus has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.54B3.48$326.66M$3.5222.20Beigene$4.18B5.24-$881.71M-$3.72-59.52 Do analysts rate LNTH or ONC? Lantheus presently has a consensus target price of $132.67, suggesting a potential upside of 69.80%. Beigene has a consensus target price of $319.00, suggesting a potential upside of 44.07%. Given Lantheus' higher probable upside, equities research analysts plainly believe Lantheus is more favorable than Beigene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Beigene 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in LNTH or ONC? 99.1% of Lantheus shares are held by institutional investors. Comparatively, 48.5% of Beigene shares are held by institutional investors. 1.5% of Lantheus shares are held by insiders. Comparatively, 6.6% of Beigene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in LNTH or ONC? Lantheus received 333 more outperform votes than Beigene when rated by MarketBeat users. However, 78.57% of users gave Beigene an outperform vote while only 66.15% of users gave Lantheus an outperform vote. CompanyUnderperformOutperformLantheusOutperform Votes34466.15% Underperform Votes17633.85% BeigeneOutperform Votes1178.57% Underperform Votes321.43% Does the media favor LNTH or ONC? In the previous week, Beigene had 4 more articles in the media than Lantheus. MarketBeat recorded 21 mentions for Beigene and 17 mentions for Lantheus. Lantheus' average media sentiment score of 0.56 beat Beigene's score of 0.29 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Beigene 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk & volatility, LNTH or ONC? Lantheus has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Comparatively, Beigene has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. SummaryLantheus beats Beigene on 10 of the 16 factors compared between the two stocks. Get Lantheus News Delivered to You Automatically Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNTH vs. The Competition Export to ExcelMetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.35B$2.62B$5.19B$8.42BDividend YieldN/A0.71%4.99%4.16%P/E Ratio12.997.5726.4119.67Price / Sales3.48338.74388.54119.76Price / Cash11.9815.7538.3134.62Price / Book6.565.496.634.48Net Income$326.66M-$65.73M$3.22B$247.85M7 Day Performance-2.53%-2.03%1.04%3.54%1 Month Performance-23.98%-2.89%6.37%11.12%1 Year Performance-1.85%-20.73%12.77%5.33% Lantheus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNTHLantheus4.4274 of 5 stars$79.78+1.2%$132.67+66.3%+0.1%$5.46B$1.54B13.27700ONCBeigene3.0894 of 5 stars$254.16-0.6%$318.88+25.5%N/A$25.14B$3.81B-30.849,000Analyst RevisionBNTXBioNTech2.6353 of 5 stars$101.10-3.7%$143.44+41.9%-0.2%$24.26B$2.75B-48.143,080Analyst ForecastPositive NewsSMMTSummit Therapeutics2.968 of 5 stars$28.02+0.4%$37.40+33.5%+385.6%$20.67B$700,000.00-100.07110Analyst UpgradePositive NewsTEVATeva Pharmaceutical Industries3.5021 of 5 stars$16.40+1.3%$23.43+42.9%-2.3%$18.59B$16.54B-11.3136,800Analyst UpgradeNews CoverageITCIIntra-Cellular Therapies0.6177 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Analyst ForecastNews CoverageGMABGenmab A/S3.3707 of 5 stars$21.55+0.3%$39.17+81.7%-35.4%$13.82B$21.53B12.391,660Earnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories1.7011 of 5 stars$13.88-0.9%$17.00+22.5%+1.6%$11.58B$311.31B22.0924,800Earnings ReportNews CoveragePositive NewsMRNAModerna4.539 of 5 stars$27.84+0.8%$53.95+93.8%-81.3%$10.76B$3.14B-3.003,900ASNDAscendis Pharma A/S3.3739 of 5 stars$170.74-0.8%$216.07+26.5%+25.9%$10.41B$363.64M-24.05640Analyst ForecastVTRSViatris2.131 of 5 stars$8.59-0.7%$10.50+22.2%-24.4%$10.19B$14.74B-11.6137,000Earnings ReportInsider Trade Related Companies and Tools Related Companies ONC Competitors BNTX Competitors SMMT Competitors TEVA Competitors ITCI Competitors GMAB Competitors RDY Competitors MRNA Competitors ASND Competitors VTRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNTH) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.